End Price Gouging for Medications Act
Latest Action
Referred to the Subcommittee on Health.
Official Summary
Official summary has not been imported yet.
GovScope Watchdog™
AI Government Intelligence™The End Price Gouging for Medications Act (H.R. 4215) is a legislative proposal introduced in the 118th Congress aimed at addressing the issue of excessive pricing for medications. The bill seeks to establish measures to prevent price gouging in the pharmaceutical sector, potentially through regulatory or enforcement mechanisms. As of the latest update, the bill has been referred to the Subcommittee on Health but has not advanced further and is currently classified as failed or expired. No official summary or full text is available to provide detailed provisions or mechanisms within the bill.
H.R. 4215 intended to curb excessive medication pricing but did not progress beyond initial committee referral and is now expired.
- The bill focuses on preventing price gouging specifically for medications.
- It was introduced in the House during the 118th Congress.
- The latest legislative action was referral to the Subcommittee on Health on December 17, 2024.
- The bill is currently classified as failed or expired, indicating no enactment.
- No official summary or full text is publicly available to detail specific provisions.
['Consumers and patients who purchase medications', 'Healthcare providers concerned with medication affordability', 'Public health agencies monitoring drug pricing']
['Lack of detailed text limits understanding of enforcement mechanisms or authority granted.', 'Potential challenges in defining and proving price gouging within pharmaceutical markets.', 'Implementation costs and administrative oversight requirements are unknown due to missing text.', 'Unclear how the bill interacts with existing drug pricing regulations or market dynamics.']
The bill was introduced in the House of Representatives during the 118th Congress and referred to the Subcommittee on Health. It did not advance beyond this stage and is now classified as failed or expired. The absence of an official summary or full text limits insight into legislative debate or support. The policy area is health, specifically focusing on medication pricing.
Hidden impact flags detected: 2
GovScope reviewed 2 policy-risk categories. Hover for a quick definition. Click detected flags for bill-specific details.
['Potential influence on pharmaceutical pricing practices if similar legislation is introduced in the future.', 'May prompt increased public and legislative attention to drug pricing issues despite failure to pass.', 'Could affect stakeholder strategies in healthcare and pharmaceutical sectors regarding pricing transparency.']
The absence of both an official summary and the full bill text significantly limits transparency and the ability to assess the bill's detailed provisions, enforcement mechanisms, and fiscal implications. The bill's failure to advance beyond subcommittee referral further restricts insight into legislative deliberations or amendments. These gaps highlight challenges in public oversight and informed analysis of proposed legislation.
GovScope Intelligence Roadmap
Future bill intelligence will connect sponsors, committee referrals, related votes, campaign finance, disclosures, and stock trades into one legislative intelligence view.